|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lockshin RA and Williams CM: Programmed
cell death-I. Cytology of degeneration in the intersegmental
muscles of the Pernyi silkmoth. J Insect Physiol. 11:123–133. 1965.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yan F, Gou L, Yang J, Chen L, Tong A, Tang
M, Yuan Z, Yao S, Zhang P and Wei Y: A novel pro-apoptosis gene
PNAS4 that induces apoptosis in A549 human lung adenocarcinoma
cells and inhibits tumor growth in mice. Biochimie. 91:502–507.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yang WT, Chen DL, Zhang FQ, Xia YC, Zhu
RY, Zhou DS and Chen YB: Experimental study on inhibition effects
of the XAF1 gene against lung cancer cell proliferation. Asian Pac
J Cancer Prev. 15:7825–7829. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang WT, Chen DL, Zhang FQ, Xia YC, Zhu
RY, Zhou DS and Chen YB: Experimental study on inhibition effects
of the XAF1 gene against lung cancer cell proliferation. Asian Pac
J Cancer Prev. 15:7825–7829. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ashkenazi A, Pai RC, Fong S, Leung S,
Lawrence DA, Marsters SA, Blackie C, Chang L, McMurtrey AE, Hebert
A, et al: Safety and antitumor activity of recombinant soluble Apo2
ligand. J Clin Invest. 104:155–162. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hao C, Song JH, Hsi B, Lewis J, Song DK,
Petruk KC, Tyrrell DL and Kneteman NM: TRAIL inhibits tumor growth
but is nontoxic to human hepatocytes in chimeric mice. Cancer Res.
64:8502–8506. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lawrence D, Shahrokh Z, Marsters S,
Achilles K, Shih D, Mounho B, Hillan K, Totpal K, DeForge L, Schow
P, et al: Differential hepatocyte toxicity of recombinant
Apo2L/TRAIL versions. Nat Med. 7:383–385. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Arrieta O, Saavedra-Perez D, Kuri R,
Aviles-Salas A, Martinez L, Mendoza-Posada D, Castillo P, Astorga
A, Guzman E and De la Garza J: Brain metastasis development and
poor survival associated with carcinoembryonic antigen (CEA) level
in advanced non-small cell lung cancer: A prospective analysis. BMC
Cancer. 9:1192009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Brown JM and Attardi LD: The role of
apoptosis in cancer development and treatment response. Nat Rev
Cancer. 5:231–237. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liston P, Fong WG and Korneluk RG: The
inhibitors of apoptosis: There is more to life than Bcl2. Oncogene.
22:8568–8580. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Straszewski-Chavez SL, Visintin IP,
Karassina N, Los G, Liston P, Halaban R, Fadiel A and Mor G: XAF1
mediates tumor necrosis factor-alpha-induced apoptosis and X-linked
inhibitor of apoptosis cleavage by acting through the mitochondrial
pathway. J BiolChem. 282:13059–13072. 2007.
|
|
14
|
Fong WG, Liston P, Rajcan-Separovic E, St
Jean M, Craig C and Korneluk RG: Expression and genetic analysis of
XIAP-associated factor 1 (XAF1) in cancer cell lines. Genomics.
70:113–122. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Finnberg N and El-Deiry WS: Selective
TRAIL-induced apoptosis in dysplastic neoplasia of the colon may
lead to new neoadjuvant or adjuvant therapies. Clin Cancer Res.
12:4132–4136. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jalving M, de Jong S, Koornstra JJ,
Boersma-van Ek W, Zwart N, Wesseling J, de Vries EG and Kleibeuker
JH: TRAIL induces apoptosis in human colorectal adenoma cell lines
and human colorectal adenomas. Clin Cancer Res. 12:4350–4356. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang L and Fang B: Mechanisms of
resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther.
12:228–237. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Herbst RS, Mendolson DS, Ebbinghaus S,
Gordon MS, O'Dwyer P, Lieberman G, Ing J, Kurzrock R, Novotny W and
Eckhardt G: A phase I safety and pharmacokinetic (PK) study of
recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients
with advanced cancer. J ClinOncol. 24:1242006.
|
|
19
|
Soria JC, Mark Z, Zatloukal P, Szima B,
Albert I, Juhász E, Pujol JL, Kozielski J, Baker N, Smethurst D, et
al: Randomized phase II study of dulanermin in combination with
paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell
lung cancer. J Clin Oncol. 29:4442–4451. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yee L, Fanale M, Dimick K, Calvert S,
Robins C, Ing J, Ling J, Novotny W, Ashkenazi A and Burris H: A
phase IB safety and pharmacokinetic (PK) study of recombinant human
Apo2L/TRAIL in combination with rituximab in patients with
low-grade non-Hodgkin lymphoma. J ClinOncol. 25:80782007.
|
|
21
|
Tu SP, Liston P, Cui JT, Lin MC, Jiang XH,
Yang Y, Gu Q, Jiang SH, Lum CT, Kung HF, et al: Restoration of XAF1
expression induces apoptosis and inhibits tumor growth in gastric
cancer. Int J Cancer. 125:688–697. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tu SP, Sun YW, Cui JT, Zou B, Lin MC, Gu
Q, Jiang SH, Kung HF, Korneluk RG and Wong BC: Tumor suppressor
XIAP-associated factor 1 (XAF1) cooperates with tumor necrosis
factor-related apoptosis-inducing ligand to suppress colon cancer
growth and trigger tumor regression. Cancer. 116:1252–1263. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Alnemri ES, Livingston DJ, Nicholson DW,
Salvesen G, Thornberry NA, Wong WW and Yuan J: Human ICE/CED-3
protease nomenclature. Cell. 87:1711996. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cohen GM: Caspases: The executioners of
apoptosis. Biochem J. 326:1–16. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang J and Lenardo MJ: Roles of caspases
in apoptosis, development, and cytokine maturation revealed by
homozygous gene deficiencies. J Cell Sci. 113:753–757.
2000.PubMed/NCBI
|
|
26
|
Tewari M, Quan LT, O'Rourke K, Desnoyers
S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS and Dixit VM:
Yama/CPP32beta, a mammalian homolog of CED-3, is a CrmA-inhibitable
protease that cleaves the death substrate poly(ADP-ribose)
polymerase. Cell. 81:801–809. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Virág L, Robaszkiewicz A, Rodriguez-Vargas
JM and Oliver FJ: Poly(ADP-ribose) signaling in cell death. Mol
Aspects Med. 34:1153–1167. 2013. View Article : Google Scholar : PubMed/NCBI
|
